Citigroup Inc Oric Pharmaceuticals, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Oric Pharmaceuticals, Inc. stock. As of the latest transaction made, Citigroup Inc holds 46,000 shares of ORIC stock, worth $391,000. This represents 0.0% of its overall portfolio holdings.

Number of Shares

46,000

Previous 27,490 67.33%

Holding current value

$391,000

Previous $194,000 142.78%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$7.52 - $11.9 $139,195 - $220,269	18,510 Added 67.33%	46,000 $471,000
Q2 2024 Aug 12, 2024	SELL	$6.63 - $12.93 $705,538 - $1.38 Million	-106,416 Reduced 79.47%	27,490 $194,000
Q1 2024 May 10, 2024	BUY	$8.04 - $16.03 $1.02 Million - $2.04 Million	127,343 Added 1940.32%	133,906 $1.84 Million
Q4 2023 Feb 09, 2024	BUY	$5.41 - $9.43 $35,370 - $61,653	6,538 Added 26152.0%	6,563 $60,000
Q3 2023 Nov 09, 2023	SELL	$6.05 - $9.28 $70,173 - $107,638	-11,599 Reduced 99.78%	25 $0
Q2 2023 Aug 10, 2023	SELL	$4.95 - $8.4 $165,646 - $281,097	-33,464 Reduced 74.22%	11,624 $90,000
Q1 2023 May 11, 2023	BUY	$4.26 - $6.75 $192,074 - $304,344	45,088 New	45,088 $257,000
Q3 2022 Nov 10, 2022	SELL	$3.15 - $5.24 $1,499 - $2,494	-476 Reduced 50.11%	474 $2,000
Q2 2022 Aug 10, 2022	SELL	$2.7 - $7.07 $13,478 - $35,293	-4,992 Reduced 84.01%	950 $4,000
Q1 2022 May 12, 2022	SELL	$4.54 - $16.1 $251,021 - $890,185	-55,291 Reduced 90.3%	5,942 $32,000
Q4 2021 Feb 10, 2022	BUY	$12.01 - $20.3 $416,506 - $704,004	34,680 Added 130.61%	61,233 $900,000
Q3 2021 Nov 10, 2021	BUY	$15.9 - $25.22 $422,192 - $669,666	26,553 New	26,553 $556,000

Others Institutions Holding ORIC

# of Institutions

124

Shares Held

66.6M

Call Options Held

7.8K

Put Options Held

700

View Full List

About Oric Pharmaceuticals, Inc.

Ticker ORIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,576,700
Market Cap $336M
Description
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...

More about ORIC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account